Bellicum Pharma

Striving to deliver cures through controllable cell therapy

[Bellicum Pharma @BellicumPharma]

Bellicum $BLCM presents encouraging early data for BPX-601 in #prostatecancer at #ASCOGU23 today. 4 of 8 patients with mCRPC achieved PSA50. details here https://t.co/ftsZHQgIdF

[Bellicum Pharma @BellicumPharma]

Bellicum's $BLCM abstract with early Phase 1 results for its lead GoCAR-T product candidate, BPX-601, in patients with #prostatecancer has been accepted for poster presentation at #ASCO GU on Feb 16 in San Francisco. The trial is ongoing. https://t.co/Y6ZhHuOrw5

[Bellicum Pharma @BellicumPharma]

Encouraging findings from #UNC Lineberger reinforce the potential benefit of the Bellicum's $BLCM CaspaCIDe safety switch and rimiducid in resolving #CARTcell related adverse events. more details here https://t.co/CkzkrmuoTT

[Bellicum Pharma @BellicumPharma]

Bellicum Pharmaceuticals recently reported financial results for third quarter 2022 and provided a corporate update and timelines for clinical data readouts. more information here: https://t.co/yOt8MBhhf5

[Bellicum Pharma @BellicumPharma]

Join Rick Fair, CEO, Bellicum, for his presentation at Cell & Gene Meeting on the Mesa Oct 11, details here: https://t.co/DFGXIqQft7

[Bellicum Pharma @BellicumPharma]

Bellicum $BLCM will be participating in the WCWainwright investor conference beginning on Sep 12. to catch the presentation go to https://t.co/TyuwTDMUKH

[Bellicum Pharma @BellicumPharma]

Bellicum Pharmaceuticals $BLCM has reported 2Q 2022 financial results and provided an operational update, more information here: https://t.co/Nac7upkxAe

[Bellicum Pharma @BellicumPharma]

Bellicum Pharmaceuticals $BLCM has reported 4Q and full year 2021 financial results and provided an operational update. more info here: https://t.co/fXY4j7rf8N

[Bellicum Pharma @BellicumPharma]

$BLCM CEO Rick Fair is presenting an overview of recent corp progress at the BRiley oncology conference thursday jan 27 at 4 pm ET. https://t.co/r2woeWBn4o

[Bellicum Pharma @BellicumPharma]

Bellicum $BLCM news, now in compliance with the continued listing requirements of The Nasdaq Capital Market, see more details here https://t.co/KXSMPm7U3Q.

[ICR Healthcare @ICRHealthcare]

10 ways to prepare for the 2022 @jpmorgan Healthcare Conference: https://t.co/GfPrcPbnbx

[Bellicum Pharma @BellicumPharma]

Bellicum $BLCM announces positive data from Phase 1/2 GoCAR-T studies and $35 million private placement equity financing #celltherapy, #cancer https://t.co/IGvmtOWfL3

[Bellicum Pharma @BellicumPharma]

see CEO Rick Fair's interview with genetherapylive discussing BLCM's cell therapy programs. $BLCM https://t.co/hH37Z4rxQg

[Bellicum Pharma @BellicumPharma]

Bellicum Pharmaceuticals $BLCM has announced 3Q financials and provided an operational update here: https://t.co/Bbf1J7Vk46

[Bellicum Pharma @BellicumPharma]

Developing Safer, Next-Generation CAR T-Cell Therapies https://t.co/hH37Z4J9eQ via @genetherapylive

[Bellicum Pharma @BellicumPharma]

Are you attending the @HCWCO Global investor Conference? View the recorded presentation by $BLCM CEO Rick Fair, starting on Sept 13 at 7 a.m. ET #HCW23Global

[Bellicum Pharma @BellicumPharma]

We are participating in the @HCWCO Global Investment Conference this month. Details here: https://t.co/LONXSVbnXD #HCW23Global $BLCM

[Bellicum Pharma @BellicumPharma]

@BellicumPharma enters additional license agreement with MDAnderson for use of CaspaCIDe safety switch in cell therapies. @MDAndersonNews $BLCM https://t.co/KODNYf4kna

[Bellicum Pharma @BellicumPharma]

Bellicum BLCM$ establishes agreement with UNC Lineberger and Mass General and Mass General for CaspaCIDe safety switch find more here https://t.co/7xF1J3o7cT

[Bellicum Pharma @BellicumPharma]

Bellicum $BLCM has reported financial results for 1Q 2021 and povided corp update. https://t.co/2CNm40J9KW